Merck, known as MSD outside of Canada and the U.S., recently announced that it now has been committed to innovation and care in HIV/AIDS for 30 years.
The company’s commitment to treating these illnesses first began with a research and development program in the 1980s, the earliest years of the HIV/AIDS epidemic. Now the program has started its fourth decade.
“The global health community has made significant progress in the fight against HIV and Merck is proud of our role in this fight, starting at the outset of the epidemic, and continuing to this day,” Daria Hazuda, vice president and therapeutic area head for infectious disease and vaccines, said. “Although antiretroviral therapy has advanced the management of HIV-1, much work remains to be done. We will continue to collaborate with scientists, clinicians, patient advocates and the global health community as we work together towards a common goal of eradicating this disease.”
Merck is celebrating this 30-year span with a new commitment, “Positively Committed.” The campaign emphasizes Merck’s contributions, such as creating innovative therapies that are designed to fulfill the unmet medical needs of people with HIV-1 infections.
“Effective treatments for HIV-1 infection were a distant hope in the 1980s, but collaborative scientific discovery and effective advocacy have made them possible today," Merck Executive Vice President Julie Gerberding said. “I'm proud that Merck is committed to sustaining our contributions to the treatment of this infection around the world.”